These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31191178)

  • 1. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.
    Mealy MA; Boscoe A; Caro J; Levy M
    Int J MS Care; 2019; 21(3):129-134. PubMed ID: 31191178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis.
    Kim S; Lee EJ; Kim KW; Seo D; Moon S; Kim KK; Lim YM
    Mult Scler Relat Disord; 2022 Feb; 58():103500. PubMed ID: 35032884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand.
    Siritho S; Thavorncharoensap M; Chanatittarat C; Pasogpakdee P; Apiwattanakul M; Prayoonwiwat N; Chankrachang S; Riewpaiboon A; Chaikledkaew U
    Mult Scler Relat Disord; 2018 Aug; 24():151-156. PubMed ID: 30015079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.
    Levy M; Haycox AR; Becker U; Costantino C; Damonte E; Klingelschmitt G; von Büdingen HC; Wallenstein G; Maio DD; Szczechowski L
    Mult Scler Relat Disord; 2022 Jan; 57():103332. PubMed ID: 35158426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health utilities and costs for neuromyelitis optica spectrum disorder.
    Hughes DA; Bourke S; Jones A; Bhatt R; Huda S; Mutch K; Jacob A
    Orphanet J Rare Dis; 2022 Apr; 17(1):159. PubMed ID: 35392962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
    Royston M; Kielhorn A; Weycker D; Shaff M; Houde L; Tanvir I; Bhattacharyya S; Levy M
    Neurol Ther; 2021 Dec; 10(2):767-783. PubMed ID: 34046846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
    Du C; Zeng P; Han JR; Zhang TX; Jia D; Shi FD; Zhang C
    Front Immunol; 2021; 12():660230. PubMed ID: 34745082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.
    Hyun JW; Jang H; Yu J; Park NY; Kim SH; Huh SY; Kim W; Park MS; Oh J; Park KD; Kim HJ
    J Clin Neurol; 2020 Jan; 16(1):124-130. PubMed ID: 31942768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran.
    Barzegar M; Badihian S; Mirmosayyeb O; Ashtari F; Jamadi M; Emami S; Jahani L; Safavi A; Shaygannejad V
    Mult Scler Relat Disord; 2018 May; 22():161-165. PubMed ID: 29775851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders.
    Schmidt F; Zimmermann H; Mikolajczak J; Oertel FC; Pache F; Weinhold M; Schinzel J; Bellmann-Strobl J; Ruprecht K; Paul F; Brandt AU
    Mult Scler Relat Disord; 2017 Jan; 11():45-50. PubMed ID: 28104256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.
    Mendoza TR; Dueck AC; Shi Q; Ma H; Zhang J; Qian Y; Cleeland CS
    Eur J Pain; 2018 Mar; 22(3):565-571. PubMed ID: 29082574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina.
    Fernández VC; Alonso N; Melamud L; Villa AM
    Mult Scler Relat Disord; 2018 Jan; 19():40-43. PubMed ID: 29125969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of psychiatric distress and physical disability on quality of life in neuromyelitis optica spectrum disorder and chronic autoimmune demyelinating polyneuropathies.
    Yalachkov Y; Soydaş D; Uhlmann V; Behrens M; Frisch S; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2021 Feb; 48():102711. PubMed ID: 33383364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience.
    Huang W; ZhangBao J; Chang X; Wang L; Zhao C; Lu J; Wang M; Ding X; Xu Y; Zhou L; Li D; Behne MK; Behne JM; Yeaman MR; Katz E; Lu C; Quan C;
    Mult Scler Relat Disord; 2020 Nov; 46():102542. PubMed ID: 33296965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder.
    Zhang X; Pei L; Xu Y; Zhang Y; Lu Z; Song S; Tian Y; Zhao X; Yin H; Wang W; Huang Y
    Mult Scler Relat Disord; 2022 Dec; 68():104213. PubMed ID: 36223704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients.
    Yang L; Li W; Xie Y; Ma S; Zhou X; Huang X; Tan S
    BMC Neurol; 2023 Mar; 23(1):112. PubMed ID: 36941592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life Among Patients With Acute Ischemic Stroke and Large Vessel Occlusion in the ESCAPE Trial.
    Joundi RA; Rebchuk AD; Field TS; Smith EE; Goyal M; Demchuk AM; Dowlatshahi D; Poppe AY; Williams DJ; Mandzia JL; Buck BH; Jadhav AP; Pikula A; Menon BK; Hill MD
    Stroke; 2021 May; 52(5):1636-1642. PubMed ID: 33691504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between subjective and objective measurements of spasticity in neuromyelitis optica spectrum disorder patients.
    Jinkarn N; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
    Mult Scler Relat Disord; 2022 Feb; 58():103517. PubMed ID: 35032877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.